EMD Serono Names Miguel Fernández Alcalde Head of Global Commercial Strategy, Appoints Monia Vial to Lead North America
EMD Serono, the Healthcare business of Merck KGaA in the United States and Canada, has announced a significant leadership transition that reshapes the commercial organization at a key moment for the company’s healthcare business. The company said Miguel Fernández Alcalde will become Head of Global Commercial Strategy, while Monia Vial has been appointed President of EMD Serono and Head of North America, succeeding Fernández Alcalde in the role.
The appointments mark an important leadership shift for EMD Serono as the company works to strengthen its commercial operations across global and regional markets while continuing to expand its portfolio in specialty care, rare disease, oncology, fertility, and other therapeutic areas. The changes also come as the organization navigates a broader transformation in its healthcare business, with an emphasis on portfolio growth, pipeline advancement, and deeper alignment between global strategy and local market execution.
In announcing the move, the company highlighted Fernández Alcalde’s extensive internal leadership experience and Vial’s long track record in rare disease and pharmaceutical commercialization as two factors that will help position the business for its next phase of growth.
Danny Bar-Zohar, Chief Executive Officer of Healthcare and a member of the Executive Board of Merck KGaA, said Fernández Alcalde has consistently demonstrated the strategic vision, adaptability, and patient focus required for the newly expanded role. He noted that over the course of his tenure, Fernández Alcalde has shown the ability to lead across multiple geographies, business functions, and levels of responsibility, making him well suited to guide the company’s global commercial strategy going forward.
Bar-Zohar also pointed to Vial’s appointment as a strong addition to the North American leadership team, emphasizing her experience in the United States as well as her international perspective. He said Vial has spent the last several years building a rare disease franchise and delivering results across multiple brands, product launches, and therapeutic indications, giving her a strong foundation to lead EMD Serono’s U.S. and Canadian business.
Fernández Alcalde Takes on Global Commercial Strategy Role
Fernández Alcalde’s appointment to Head of Global Commercial Strategy places him in a role that sits at the center of how EMD Serono and its parent organization plan to translate scientific innovation into commercial success. The function is a critical one for large pharmaceutical and biotechnology companies, serving as the bridge between research and development, product planning, launch execution, market access, and long-term portfolio growth.
He succeeds Andrew Paterson, who is retiring after 31 years with Merck KGaA. Paterson’s departure marks the end of a lengthy tenure at the company and opens the door for Fernández Alcalde to help shape the next chapter of the healthcare business’s commercial strategy.
Before taking on this new assignment, Fernández Alcalde served as President of EMD Serono and Head of North America, overseeing the company’s healthcare operations in the U.S. and Canada. During his time in that role, he was responsible for one of the most strategically important regions in the company’s healthcare business, helping guide the organization through an increasingly competitive pharmaceutical market while supporting the commercialization of its specialty care portfolio.
His experience at the company extends well beyond North America. Prior to serving as President of EMD Serono, Fernández Alcalde held several senior leadership positions across Merck KGaA’s healthcare business, including Chief Operating Officer of EMD Serono, Head of Global Business Excellence & Innovation, and General Manager for Finland and Spain. Those assignments gave him experience across commercial operations, strategic planning, operational leadership, and business transformation—an unusually broad background that the company believes will be valuable in steering global commercial strategy.
Fernández Alcalde joined the organization in 2014 and has since built a career that spans both local market leadership and enterprise-level strategic roles. His academic background includes a Bachelor’s degree in Pharmacy from the University Complutense in Madrid, an MBA from the University of Alcalá de Henares, and a Master’s degree in Management from IESE Business School.
Commenting on his new role, Fernández Alcalde said global commercial strategy is central to how the company brings its science and innovation to patients around the world. He indicated that, working with teams across geographies, he intends to help drive growth, accelerate the portfolio, and focus on delivering outcomes that matter to patients. His remarks underscore the increasingly integrated nature of commercial strategy in the biopharmaceutical sector, where companies must align product development, launch readiness, market access, and regional execution more closely than ever before.
Monia Vial to Lead EMD Serono in North America
Taking over Fernández Alcalde’s former role is Monia Vial, who joins EMD Serono from Ipsen Biopharmaceuticals, where she most recently served as Senior Vice President and Head of the U.S. Rare Disease Business Unit. Her appointment signals EMD Serono’s intent to deepen its commercial expertise in high-value specialty markets, particularly as rare disease continues to be a major strategic focus across the pharmaceutical industry.
Vial brings more than 20 years of pharmaceutical leadership experience to the role, with a career spanning rare disease, oncology, hematology, business development, brand strategy, lifecycle management, and pipeline planning. Her background includes leadership of in-country profit-and-loss responsibilities, work on global brand strategy, oversight of product launches, and involvement in asset acquisition and development efforts.
That range of experience is particularly relevant for a North American leadership role at EMD Serono, where success depends not only on commercial execution but also on navigating a complex healthcare environment shaped by payer dynamics, specialty distribution, competition, and the increasing importance of differentiated therapies in areas such as oncology, immunology, neurology, and rare disease.
At Ipsen, Vial played a central role in leading the company’s U.S. rare disease business, a segment that has become one of the most strategically attractive areas in biopharma because of its focus on highly specialized therapies, smaller patient populations, and often significant unmet medical need. Her experience building and scaling rare disease brands is likely to be particularly valuable as EMD Serono continues to evaluate how best to position its current portfolio and future pipeline assets in the North American market.
Before joining Ipsen, Vial held roles of increasing responsibility at several major pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb, and Shire Pharmaceuticals. She began her professional career in consultancy before moving into the pharmaceutical sector, where she developed experience across commercial strategy, product development support, and market-building activities.
Her academic credentials include a Doctor of Pharmacy (PharmD) from the University of Pharmacy, Paris, as well as a Master’s degree in Marketing from HEC Paris. That combination of scientific training and commercial expertise has become increasingly valuable in the modern pharmaceutical landscape, where leaders are often expected to bridge scientific understanding with market strategy and operational execution.
In a statement, Vial described her move to EMD Serono as a unique opportunity at a particularly dynamic moment for the company. She said the organization is undergoing an exciting transformation and that its current portfolio and pipeline create meaningful opportunities to make a difference for patients. She also emphasized her intention to meet teams across the United States and Canada, learn from them, and work collaboratively to drive impact across the business.
Leadership Changes Reflect a Broader Strategic Moment for EMD Serono
Taken together, the appointments of Fernández Alcalde and Vial reflect a broader strategic moment for EMD Serono and the healthcare business of Merck KGaA. Large pharmaceutical companies are increasingly rethinking how they structure leadership around commercialization, especially as product portfolios become more specialized and launch environments more complex. Global commercial strategy has become a central function for aligning pipeline priorities, launch planning, pricing and access strategies, and local execution across regions.
At the same time, North America remains one of the most important markets for virtually every major biopharmaceutical company. The United States in particular continues to shape global pharmaceutical revenues, launch sequencing, and innovation strategies. Leadership of that business therefore carries outsized significance, particularly for companies looking to compete in rare disease, oncology, fertility, and other specialty areas.
By moving Fernández Alcalde into a broader global strategy role while bringing in Vial to lead North America, EMD Serono appears to be balancing continuity with fresh external perspective. Fernández Alcalde offers deep institutional knowledge and a strong understanding of the company’s internal operations, while Vial brings outside commercial experience and a track record in rare disease growth and product execution.
Both executives will be based in Boston, a major hub for the biotechnology and pharmaceutical industry in the United States. They will also serve as members of the Healthcare Executive Committee, positioning them to help shape both the strategic direction and day-to-day execution of the company’s healthcare priorities.
The changes come as EMD Serono continues to evolve its position in a healthcare market that demands greater speed, sharper commercial focus, and closer integration between science and strategy. With a new leader for North America and a new head of global commercial strategy in place, the company is signaling that it intends to strengthen both its regional leadership and its global commercial engine as it prepares for the next phase of growth.
About EMD Serono, Inc.
EMD Serono – the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada – aspires to create, improve and prolong life for people living with difficult-to-treat conditions like infertility, multiple sclerosis and cancer. The business is imagining the future of healthcare by working to translate the discovery of molecules into potentially meaningful outcomes for people with serious unmet medical needs. EMD Serono’s global roots go back more than 350 years with Merck KGaA, Darmstadt, Germany. Today, the business has approximately 1,050 employees around the country with commercial, clinical and research operations in Massachusetts. www.emdserono.com.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2025, Merck KGaA, Darmstadt, Germany, generated sales of € 21.1 billion in 65 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
